Threshold Pharmaceuticals, Inc., based in South San Francisco,
California, is a research-driven biotechnology company dedicated to the discovery and development of tumor targeted therapies to improve the lives of patients with cancer.
- April 22, 2015
- Threshold Pharmaceuticals Reports Preclinical Data Suggesting That TH-4000 May Overcome Resistance to Conventional EGFR Tyrosine Kinase Inhibitors
- April 16, 2015
- Threshold Pharmaceuticals to Host Analyst and Investor Day on April 24 in New York City
- March 19, 2015
- Threshold Pharmaceuticals to Present Data Supporting Planned Phase 2 Trials of TH-4000, a Hypoxia-Activated, Irreversible EGFR Tyrosine Kinase Inhibitor